Poseida Therapeutics Highlights Recent Progress, Strategic Priorities And Anticipated 2024 Key Milestones
Portfolio Pulse from Benzinga Newsdesk
Poseida Therapeutics, Inc. (NASDAQ:PSTX) reported positive early clinical data for its allogeneic myeloma cell therapy P-BCMA-ALLO1 at ASH 2023, indicating potential to compete with autologous CAR-T. The company plans to update clinical data for P-BCMA-ALLO1 and P-MUC1C-ALLO1 in 2024 and expects to dose the first patient in the P-CD19CD20-ALLO1 trial early 2024. Poseida expanded its partnership with Roche, accelerating milestone achievements. The company also highlighted progress in its non-viral gene therapy portfolio, including P-FVIII-101 for Hemophilia A. Poseida's cash position is expected to fund operations into the second half of 2025, supported by business development and partnerships.
January 04, 2024 | 1:03 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Poseida Therapeutics reported positive clinical data for P-BCMA-ALLO1 and plans for further updates in 2024. The company's partnership with Roche has been expanded, and its financial position is strong, with funding into the second half of 2025.
The positive clinical data for P-BCMA-ALLO1 suggests potential for a competitive product in the CAR-T space, which could drive investor interest and stock price. The expanded partnership with Roche and a strong cash position provide additional confidence in the company's ability to continue its operations and development efforts without immediate financial concerns. These factors are likely to be viewed positively by investors in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100